A large menopause study found shifts in laboratory measures. Understand the findings, expert cautions and questions for a midlife health discussion.
On October 13, 2026, a Nature Medicine press release reported findings from an analysis of more than 300 million laboratory-test results from over one million women in the United States and Israel. The study examined how patterns in laboratory tests shifted around the final menstrual period.
The research challenges a picture of menopause-related biological change as a mostly gradual process. ABC News Australia compared its conclusions with the long-running Study of Women’s Health Across the Nation (SWAN), which followed women over time and suggested that some broad changes unfold gradually.
The question is not whether menopause deserves attention beyond reproductive symptoms. It is whether the transition includes a sharper turning point in multiple laboratory measures than a gradual-change model would suggest. That places the findings within the wider discussion of hormonal change across midlife, rather than treating them as a new treatment rule.
The scale of the work is striking, but the details matter more than the headline size. According to the Nature Medicine release and the Weizmann Institute of Science’s account, the researchers reported the following patterns:
Weizmann professor Uri Alon said the research “extends the window for potential preventive care to almost a decade before menopause.” That is the lead researcher’s interpretation of what the results could make possible, rather than an established screening recommendation.
Independent specialists interviewed by ABC were more cautious about the language used to describe the pattern. Martha Hickey, head of menopause services at The Women’s Hospital Victoria, called the “physiological cliff” framing “unnecessarily alarming.” General practitioner Elina Safro also questioned the cliff theory while supporting health vigilance in midlife.
The central limits sit in the study design. The analysis used existing records and self-reported information about the last menstrual period, according to ABC. The precise age of that milestone was generally unavailable in the datasets, which is why the team developed its alignment method. This differs from prospectively following each woman through the transition.
The reported cliff is a population-level pattern, not a forecast of sudden decline for an individual woman. The size of the dataset does not establish that menopause caused every observed shift. A changing laboratory measure also does not by itself establish organ damage or a diagnosis.
The hormone-therapy comparison has a separate problem: women using treatment may already differ from those not using it. Hickey noted that healthier women may be more likely to receive hormone therapy. The observational findings therefore do not show that treatment prevented the shifts or that it prevents cardiovascular disease or dementia.
Taken together, those limits leave a research finding worth investigating rather than a reason to start hormone therapy solely on the basis of this study. Personal treatment decisions belong in an individualized discussion with a qualified clinician.
Endocrinologist Ada Cheung told ABC that menopause can be a useful time to discuss bone health, cholesterol, blood pressure and blood sugar. Her emphasis was on looking at relevant health questions rather than waiting for problems to arise.
That is a more practical response than treating a large dataset as a personal test order. The reporting supports a conversation about appropriate checks, not a universal new testing schedule. A proposed test is most useful to discuss in terms of what it assesses and how its result would affect care.
Questions that follow directly from that approach include:
Women do not need to dismiss changes in their bodies to avoid alarming interpretations. The useful middle ground is to describe what has changed and ask which questions deserve assessment. For related context, thinking about body composition beyond weight can help frame that discussion without turning this laboratory study into a weight-management claim.
ABC also reported that the team planned a clinical trial to investigate hormone therapy begun before periods end. That research direction addresses a different question from describing patterns in existing records: whether an intervention changes outcomes.
This study should move clinical conversations toward broader midlife health assessment while leaving preventive treatment claims to trials designed to test them.
Deciding whether a menopause study warrants a personal health discussion is where Refemina’s editorial interpretation adds context. For women weighing hormonal explanations against other possible causes, its coverage connects physical change with strength and confidence so health questions can be understood without alarm or a single-answer sales pitch.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources